Cabaletta Bio financials
$1.98−1.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross margin | — | — | — | — | — | — | — |
| Operating income | -$172.2M | -$125.1M | -$74.7M | -$54.1M | -$46.3M | -$33.8M | -$18.7M |
| Net income | -$167.9M | -$114.7M | -$67.7M | -$53.0M | -$46.3M | -$33.3M | -$17.7M |
| Net margin | — | — | — | — | — | — | — |
| Diluted EPS | $-2.10 | $-2.34 | $-1.65 | $-1.81 | $-1.80 | $-1.44 | $-4.07 |
| EBITDA | -$170.6M | -$123.4M | -$73.2M | -$53.0M | -$45.6M | -$33.5M | -$6.9M |
| Operating cash flow | -$131.1M | -$88.2M | -$53.5M | -$46.4M | -$34.1M | -$26.8M | -$16.0M |
| Free cash flow | -$132.3M | -$90.4M | -$54.2M | -$48.8M | -$35.3M | -$27.4M | -$16.7M |
| Diluted shares | 79.9M | 49.5M | 42.7M | 32.7M | 25.7M | 23.1M | 5.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $83.0M | $164.0M | $193.2M | $81.6M | $122.2M | $101.4M |
| Short-term investments | $50.6M | $0.00 | $48.0M | $24.9M | $0.00 | $7.2M |
| Total debt | $23.6M | $9.2M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $165.1M | $185.0M | $253.7M | $117.0M | $126.3M | $114.7M |
| Total liabilities | $53.0M | $32.7M | $17.5M | $12.4M | $8.4M | $5.2M |
| Shareholders' equity | $112.1M | $152.3M | $236.2M | $104.5M | $118.0M | $109.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology